|Application ||WB, IHC-P, IHC-F, FC|
|Calculated MW||81538 Da|
|Shelf Life||18 months from date of despatch.|
|Other Names||CD44 antigen, CDw44, Epican, Extracellular matrix receptor III, ECMR-III, GP90 lymphocyte homing/adhesion receptor, HUTCH-I, Heparan sulfate proteoglycan, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, Phagocytic glycoprotein I, PGP-I, CD44, CD44, LHR, MDU2, MDU3, MIC4|
|Target/Specificity||Mouse anti-Human CD44v5 antibody, clone VFF-8 specifically recognises an epitope encoded by exon v5 on the variant region of human CD44. CD44 is a type I transmembrane glycoprotein of variable molecular weight ranging from ~90 kDa to ~220 kDa depending on alternate splicing of the variable region exons and on the degree of glycosylation. CD44 is expressed on multiple cell types and is involved in multiple functions including cell-cell interactions and cell-extracellular matrix binding. Hyaluronan, a high molecular weight polysaccharide component of the extracellular matrix acts as the principal ligand for the CD44 receptor (Laurent and Fraser 1992).CD44 isoforms containing one or more sequences encoded by the variant region exons have a much more restricted expression pattern both in terms of organ specificity and immune activation (Mackayet al.1994). CD44 isoforms bearing the v5 exon product have been implicated in various neoplasms including breast cancer (Tempferet al.1996), renal cell carcinoma (Wuet al.2003) and cervical cancer metastases (Kainzet al.1996).Mouse anti-Human CD44v5 antibody has proved a useful reagent for the imunohistochemical or flow cytometric evaluation of CD44 variants containing the v5exon product expression in normal and neoplasic cells (Ringelet al.2001)|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD44v5 Antibody, clone VFF-8 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Bànkfalvi, A. et al. (1998) Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.Histopathology. 33 (2): 107-16. 2. Alam, T.N. et al. (2004) Differential expression of CD44 during human prostate epithelial cell differentiation.J Histochem Cytochem. 52: 1083-90. 3. Rajarajan, A. et al. (2012) CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.PLoS One. 7: e28776. 4. Hanley, W.D. et al. (2006) Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells.FASEB J. 20: 337-9. 5. Chaiyarit, P. et al. (2008) Alteration of the expression of CD44 [corrected] isoforms in oral epithelia and saliva from patients with oral lichen planus.J Clin Immunol. 28: 26-34. 6. Shirure, V.S. et al. (2015) CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions.Am J Physiol Cell Physiol. 308 (1): C68-78.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.